Ostase® BAP
Product Description
The IDS-iSYS Ostase® BAP assay is an in vitro diagnostic device intended for the quantitative determination of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity, in human serum or plasma on the IDS system.
Results are to be used in conjunction with other clinical and laboratory data to aid the clinician in the management of postmenopausal osteoporosis and Paget’s disease.
Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.
- Accurate and reliable results – providing a useful tool to identify non-adherent and non-responders to therapy.
- BAP levels are not affected by circadian variation – ease of sample collection, handling, and storage.
- BAP is cleared by the liver, not by the kidneys – levels are not affected by renal function.
- Clinically relevant measurement – as recommended in KDIGO guidelines.
- Complements the existing bone turnover panel aiding management of osteoporosis and other metabolic bone diseases.
- Ability to combine the bone turnover markers with the established IDS-iSYS 25-Hydroxy Vitamin DS – aiding management of osteoporosis and other metabolic bone diseases.
-
- Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocrine Reviews 9:437-448, 1988.
- Whyte MP. Alkaline phosphatase and the measurement of bone formation, Clinical Disorders of Bone and Mineral Metabolism. Potts JT and Frame B, eds., pp. 120-125, 1983.
- Garnero P and Delmas P. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrin Metab 77:1046-1053, 1993.
- Cooper EH, Whelan P, and Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. The Prostate 25:236-242, 1994.
- Van Straalen JP, Sanders E, Prummel MF, and Sanders GTB. Bone alkaline phosphatase as indicator of bone formation. Clin Chim Acta 201:27-33, 1991.
- Merkow RL and Lane JM. Metabolic bone disease and Paget’s disease in the elderly: II. Paget’s Disease. Clin Rheum Dis 12:70, 1986.
- kdigo.org/clinical_practice_guidelines/kdigo_guideline_for_ckd-mbd.php
- Schwarz P. et al. Paget’s disease of the bone after treatment with Denosumab: A case report. Bone 50 2012 1023–1025.
- Product Code: IS-2800 / IS-2830 CE Marked IS-2800US / IS-2830US / IS-2835US FDA Cleared
- Number of Tests: 100
- Sample Type: Serum, plasma (lithium heparin, sodium heparin) - CE Marked assay Serum - FDA Cleared assay
- Sample Volume: 50 μL plus dead volume
- Assay Range: 1 - 75 µg/L- CE Marked assay / 3 – 70 μg/L - FDA Cleared assay
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| Alpha CrossLaps® (CTX-I) EIA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| BoneTRAP® (TRAcP 5b) ELISA | CE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| N-MID® Osteocalcin | CE Marked | i10iSYS | Bone Turnover | Endocrinology | IVD |
| N-MID® Osteocalcin ELISA | CE MarkedFDA Cleared | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD |